• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lumito

2.25 SEK+10.32 %22.7, 17.26
Less than 1K followers

LUMITO

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+10.32 %
-14.02 %
-15.41 %
-66.22 %
-58.98 %
-96.60 %
-99.21 %
-99.17 %
-98.82 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
40.43M SEK
Turnover
69.27K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

23.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release20.07.2026, 10.30

Lumito reports positive results from ongoing collaborative research projects – SCIZYS demonstrates high sensitivity across multiple applications

Lumito
Regulatory press release16.07.2026, 11.00

Lumito’s founder and Board member Stefan Andersson-Engels presented at the prestigious Gordon Research Conference 2026

Lumito
Regulatory press release14.07.2026, 11.00

Lumito and Offspring Biosciences report promising initial results from pilot study evaluating automated immunohistochemistry platform

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release09.07.2026, 09.00

Lumito and Navinci initiate pilot project – promising initial results from evaluation of combined technology

Lumito
Regulatory press release01.07.2026, 08.30

Lumito appoints Pascal Bamford as new Chair of the Scientific Advisory Board

Lumito
Regulatory press release25.06.2026, 10.00

Lumito to present two scientific posters and exhibit at the European Congress of Pathology 2026 in Stockholm

Lumito
Regulatory press release11.06.2026, 13.00

Lumito strengthens Scientific Advisory Board with internationally leading experts in life science and drug development

Lumito
Regulatory press release27.05.2026, 09.00

Lumito awarded Vinnova funding to strengthen regulatory and quality capabilities during commercialisation

Lumito
Regulatory press release25.05.2026, 14.15

Subscription price for the exercise of warrants of series TO7 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026

Lumito
Regulatory press release07.05.2026, 08.30

Lumito AB publishes Interim Report Q1 2026

Lumito
Regulatory press release05.05.2026, 11.00

Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

Lumito
Regulatory press release04.05.2026, 10.00

Simpler biomarker workflows without compromising sensitivity: new white paper shows how researchers gain reproducible, quantitative IHC results in fewer steps

Lumito
Regulatory press release09.04.2026, 08.30

Lumito’s CRO strategy generates revenue through collaboration with Truly Labs AB

Lumito
Regulatory press release02.04.2026, 08.30

Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis

Lumito
Regulatory press release18.03.2026, 09.00

Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito’s UCNP imaging and Tethis’ SmartBioSurface® slides

Lumito
Regulatory press release12.03.2026, 09.15

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Lumito
Regulatory press release10.03.2026, 15.15

Lumito publishes equity research report on Lumito

Lumito
Regulatory press release10.03.2026, 11.45

Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day

Lumito
Regulatory press release20.02.2026, 08.30

Lumito AB publishes year-end report 2025

Lumito
Regulatory press release18.02.2026, 09.20

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Lumito